Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06680440 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity
A Phase 1 study, sponsored by Ascletis Pharma (China) Co., Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT06680440 is a Phase 1 study that has completed, run by Ascletis Pharma (China) Co., Limited. The registered enrollment target is 72 participants.
The verdict
NCT06680440, a Phase 1 study, has completed, sponsored by Ascletis Pharma (China) Co., Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
This is a phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, efficacy, food effect of ASC30 Tablets or ASC30 Tablets A1 in participants with obesity.
Interventions
- OTHER Placebo
- DRUG ASC30
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2024-08-26 |
| Est. Completion | 2025-04-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06680440
The ClinicalTrials.gov registry entry for NCT06680440 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ascletis Pharma (China) Co., Limited, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06680440 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06680440 about?
NCT06680440 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity". This is a phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, efficacy, food effect of ASC30 Tablets or ASC30 Tablets A1 in participants with obesity.
What is the current status of trial NCT06680440?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2024-08-26. Estimated completion is 2025-04-03.
What interventions are being tested in trial NCT06680440?
The interventions under investigation include: Placebo (OTHER), ASC30 (DRUG).
Who is sponsoring clinical trial NCT06680440?
This trial is sponsored by Ascletis Pharma (China) Co., Limited, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.